FindTrial
Sign In

PRT3789

DRUG3 trials

Sponsors

Prelude Therapeutics Inc., Prelude Therapeutics

Conditions

Advanced Solid TumorAdvanced or Metastatic Solid Tumors with a SMARCA4 MutationEsophageal CancerMetastatic Solid TumorNon-small Cell Lung CancersSMARCA4 Gene Mutationnon-small cell lung cancer (NSCLC)

Phase 1

PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation
CompletedNCT05639751
Prelude TherapeuticsAdvanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancers +1
Start: 2023-05-02End: 2025-10-01Updated: 2025-10-16

Phase 2

A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
TerminatedNCT06682806
Prelude TherapeuticsAdvanced Solid Tumor, Esophageal Cancer, Metastatic Solid Tumor +2
Start: 2025-06-03End: 2026-01-23Updated: 2026-02-02
A Phase 2, Safety and Efficacy Study of PRT3789 in Combination with Pembrolizumab in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation
CompletedCTIS2024-516889-11-00
Prelude Therapeutics Inc.Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation, Esophageal Cancer, non-small cell lung cancer (NSCLC)
Start: 2025-05-21End: 2025-08-14Target: 29Updated: 2025-07-29

Related Papers

A phase 2 safety and efficacy study of PRT3789 in combination with pembrolizumab in patients with advanced or metastatic solid tumors and a <i>SMARCA4</i> mutation.
Journal of Clinical Oncology2025-05-28
Abstract 1646: Elucidating the molecular mechanism of action of the first in human SMARCA2 selective degrader PRT3789
Cancer Research2025-04-211 citations
Selective SMARCA2 Degradation Promotes Leukemic Differentiation and Synergizes with CDK9 Inhibition to Potently Induce Death in Pre-Clinical Models of Acute Myeloid Leukemia
Blood2024-11-051 citations
SWI/SNF Complex-Deficient Undifferentiated Carcinoma of the Pancreas: Clinicopathologic and Genomic Analysis.
2024-07-319 citations
Abstract B113: Discovery of PRT3789, a first-in-class potent and selective SMARCA2 degrader in clinical trials for the treatment of patients with SMARCA4 mutated cancers
Molecular Cancer Therapeutics2023-12-012 citations
Abstract C013: Clinical biomarkers based on PK/PD modeling to guide the development for a first-in-class, highly selective SMARCA2 (BRM) degrader, PRT3789
Molecular Cancer Therapeutics2023-12-011 citations